May 2026
M	T	W	T	F	S	S
	1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

C. Ola Landgren: Presenting ADVANCE Trial Results in Multiple Myeloma at EHA25

news.med.miami.edu

Jun 16, 2025, 02:06

C. Ola Landgren: Presenting ADVANCE Trial Results in Multiple Myeloma at EHA25

C. Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:

“Thank you, EHA25, for inviting me to present our results from the randomized, multicenter ADVANCE clinical trial for the treatment of patients with newly diagnosed multiple myeloma – at the annual meeting in Milan, Italy!

The study shows that the 4-drug combination with Daratumumab-Carfilzomib-Lenalidomide-dexamethasone (Dara-KRd) delivers significantly (p<0.0001; OR=2.9) higher MRD negativity rates compared to KRd. The results are consistent across subgroups.

The progression-free survival analysis shows that at almost 3 years of follow-up, 92% of the patients treated with Dara-KRd) are are doing well and are free from progression. The study was open for enrollment, independent of transplant eligibility (transplant eligible, transplant ineligible, and transplant deferred). MRD negativity after 8 cycles of combination therapy was the primary endpoint. There were no new safety signals.

We conclude that Dara-KRd is a new standard of care for newly diagnosed multiple myeloma patients, independent of transplant eligibility.

Thank you to all patients and family who participated in the ADVANCE clinical trial for newly diagnosed multiple myeloma! Thank you to all our collaborators and thank you to our funding support!”

Hemostasis Today

Insight

C. Ola Landgren: Presenting ADVANCE Trial Results in Multiple Myeloma at EHA25

“Thank you, EHA25, for inviting me to present our results from the randomized, multicenter ADVANCE clinical trial for the treatment of patients with newly diagnosed multiple myeloma – at the annual meeting in Milan, Italy!

The study shows that the 4-drug combination with Daratumumab-Carfilzomib-Lenalidomide-dexamethasone (Dara-KRd) delivers significantly (p<0.0001; OR=2.9) higher MRD negativity rates compared to KRd. The results are consistent across subgroups.

We conclude that Dara-KRd is a new standard of care for newly diagnosed multiple myeloma patients, independent of transplant eligibility.

Thank you to all patients and family who participated in the ADVANCE clinical trial for newly diagnosed multiple myeloma! Thank you to all our collaborators and thank you to our funding support!”